Sosei Group (JP:4565) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Nxera Pharma has commenced a Phase 3 clinical trial in South Korea to evaluate its insomnia treatment, daridorexant, following its recent approval in Japan. Insomnia affects a significant portion of South Korea’s population, and this trial aims to provide further efficacy and safety data to secure marketing authorization in the country. The trial underscores Nxera’s commitment to addressing insomnia’s serious health impact and expanding its market reach in Asia.
For further insights into JP:4565 stock, check out TipRanks’ Stock Analysis page.
